Doris Ribitsch

Title: Doris Ribitsch: Innovator in Glycosylation Control

Introduction

Doris Ribitsch is a prominent inventor based in Graz, Austria. She has made significant contributions to the field of glycosylation, particularly in the quantitative control of sialylation. Her innovative work has implications for the development of glycoproteins, which are essential in various biological processes.

Latest Patents

Doris Ribitsch holds a patent titled "Quantitative control of sialylation and specific mono-sialylation." This patent focuses on the use of specific glycosyltransferase variants that have N-terminal truncation deletions. The research revealed that two different truncation variants of human β-galactoside-α-2,6-sialyltransferase I (hST6Gal-I) exhibited distinct enzymatic activities. One variant catalyzed the formation of bi-sialylated target molecules, while the other facilitated the creation of mono-sialylated target molecules. This work provides methods for recombinantly producing glycosyltransferase variants and their applications in glycoprotein sialylation.

Career Highlights

Throughout her career, Doris Ribitsch has worked with notable companies such as Roche Diagnostics Operations, Inc. and F. Hoffmann-La Roche AG. Her experience in these organizations has allowed her to advance her research and contribute to the field of biotechnology.

Collaborations

Doris has collaborated with esteemed colleagues, including Tibor Czabany and Alfred Engel. These partnerships have enriched her research and expanded the impact of her innovations.

Conclusion

Doris Ribitsch is a trailblazer in the field of glycosylation, with her patent on sialylation control showcasing her innovative spirit. Her work continues to influence the development of glycoproteins, highlighting the importance of her contributions to biotechnology.